Related Experiment Video
Updated: May 2, 2026
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.0K
Therapy of inflammatory bowel disease
1Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA. bsands@partners.org
Gastroenterology
|June 27, 2000
Summary
Recent advances in inflammatory bowel disease (IBD) treatment include targeted drug delivery and new immunosuppressive agents. Emerging therapies promise further breakthroughs in managing ulcerative colitis and Crohn
Area of Science:
- Gastroenterology and Immunology
- Pharmacology and Drug Development
Background:
- Significant progress in Inflammatory Bowel Disease (IBD) treatment over the past decade.
- Enhanced drug formulations allow targeted delivery, improving safety and efficacy.
- Immunosuppressive therapies are now standard care for IBD patients.
Purpose of the Study:
- To review current treatments for IBD.
- To provide an overview of emerging therapeutic agents for IBD.
- To highlight advances in understanding IBD pathogenesis.
Main Methods:
- Review of existing literature on IBD treatments.
- Analysis of advancements in drug formulation and biotechnology.
- Examination of novel therapeutic targets in IBD pathogenesis.
Main Results:
- Improved safety and efficacy of existing IBD medications through targeted delivery.
- Increased use of immunosuppressive agents in IBD management.
- Development of new biotechnological agents targeting key disease pathways.
Conclusions:
- The field of IBD treatment has seen substantial gains.
- Biotechnology is driving the development of novel, targeted therapies.
- Future IBD management will benefit from a deeper understanding of disease pathogenesis and advanced therapeutic options.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K